Association of Pretreatment Hippocampal Volume With Neurocognitive Function in Patients Treated With Hippocampal Avoidance Whole Brain Radiation Therapy for Brain Metastases: Secondary Analysis of NRG Oncology/RTOG 0933

Christopher D. Abraham, MD, Joseph A. Bovi, MD, Vinai Gondi, MD, Minesh P. Mehta, MD, Tammie Benzinger, MD, Christopher J. Owen, MS, Simon S. Lo, MD, Vijayananda Kundapur, MD, Paul D. Brown, MD, Alexander Y. Sun, MD, Steven P. Howard, MD, Albert S. DeNittis, MD, Clifford G. Robinson, MD, and Lisa A. Kachnic, MD

Washington University School of Medicine, Saint Louis, Missouri; Barnes-Jewish Hospital, Saint Louis, Missouri; NRG Oncology Statistics and Data Management Center, Philadelphia, Pennsylvania; Froedtert and the Medical College of Wisconsin, Milwaukee, Wisconsin; Northwestern Medicine Cancer, Warrenville, Illinois; Miami Cancer Institute, Miami, Florida; University of Washington Medical Center, Seattle, Washington; Saskatoon Cancer Centre, Saskatoon, Saskatchewan, Canada; Mayo Clinic, Rochester, Minnesota; University Health Network—Princess Margaret Hospital, Toronto, Ontario, Canada; University of Wisconsin Hospital and Clinics, Madison, Wisconsin; MainLine Health NCORP, Wynnewood, Pennsylvania; and Columbia University, New York, New York

Received 22 June 2020; accepted 5 November 2021

Abstract

Purpose: Hippocampal volume (HV) is an established predicting factor for neurocognitive function (NCF) in neurodegenerative disease. Whether the same phenomenon exists with hippocampal-avoidant whole brain radiation therapy is not known; therefore, we assessed the association of baseline HV with NCF among patients enrolled on RTOG 0933.

Sources of support: This project was supported by grants UG1CA189867 (National Cancer Center Institute Community Oncology Research Program), U10CA180868 (NRG Oncology Operations), U10CA180822 (NRG Oncology statistical and data management center), and U24CA180803 (Imaging and Radiation Oncology Core), from the National Cancer Institute.

Disclosures: Dr Benzinger reports grants and investigator-initiated research such as clinical trials from Avid Radiopharmaceuticals/Eli Lilly, clinical trials from Roche, and other from Biogen and Merck. Dr Bovi reports being a paid consultant for Elekta. Dr Brown reports receiving personal fees from UpToDate. Dr Gondi reports receiving personal fees and honoraria from UpToDate. Dr Kachnic reports receiving royalties from UpToDate and an honorarium from TRM Oncology. Dr Lo reports being a member of the Gamma Knife ICON Expert Group from Elekta AB. Dr Mehta reports receiving personal fees from Insys, Remedy, Iba, Varian, Celgene, Abbvie, Astra Zeneca, Tocagen, and Blue Earth Diagnostics and serving on the Board of Directors (Options) for Oncoceutics. Dr Pugh reports receiving salary support paid to NRG Oncology from Millennium and Pfizer-Astellas. Dr Robinson reports receiving grants and personal fees from Varian, grants from Elekta, and equity from Radiologica. All other authors have no disclosures to declare.

Data sharing statement: Research data are stored in an institutional repository and will be shared upon request to the corresponding author.

*Corresponding author: Christopher D. Abraham, MD; E-mail: cabraham@wustl.edu

https://doi.org/10.1016/j.adro.2021.100859

2452-1094 © 2021 The Authors. Published by Elsevier Inc. on behalf of American Society for Radiation Oncology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction

Metastatic disease is the most common central nervous system malignancy. Radiation therapy remains the cornerstone for a majority of these patients. Although the use of stereotactic radiation surgery is increasing, there remains a cohort of patients in which radiation surgery is not feasible or appropriate. In this cohort, whole brain radiation therapy (WBRT) remains the preferred treatment option. However, all forms of brain radiation therapy, including WBRT, have well-known deleterious effects on neurocognitive function (NCF). As overall survival in metastatic disease continues to improve, there has been considerable interest in reducing iatrogenic neurocognitive toxic effects associated with this form of therapy.

The subgranular zone of the hippocampus houses a major stem-cell niche, and continuous neuroregeneration from this radiosensitive structure has been theorized to be responsible for the formation of cells that participate in the formation and imprinting of new memory. To mitigate the negative effects of WBRT, NCTN GROUP conducted a single-arm phase 2 trial, RTOG 0933, to determine the feasibility and safety of hippocampal-avoidant WBRT (HA-WBRT) and its effect on NCF. Hypothesis-generating preliminary data from this study noted that HA-WBRT reduces the risk of neurocognitive decline at 4 months relative to historical controls treated with standard WBRT. Given these positive results, a randomized trial of WBRT versus HA-WBRT (NRG CC001) has been completed, and positive results have been presented in abstract form.

Although HA-WBRT was noted to reduce the risk of neurocognitive decline, patient-specific variables were also found to be correlated with NCF, such as age and the presence of pre-existing neurologic symptoms. However, the role of patient-specific variables and their effect on NCF has not been well investigated in patients receiving HA-WBRT.

A robust body of data exploring patient-specific imaging biomarkers of neurocognitive decline extracted from magnetic resonance imaging (MRI) exists in neurodegenerative diseases such as Alzheimer’s. Hippocampal volume (HV) has emerged as a strong predictor, with smaller HV closely associated with decreased NCF. However, HV has not been well explored as an imaging biomarker in patients with brain metastases, a population with multiple competing reasons for NCF decline including the metastases themselves.

We hypothesized that HV may be predictive of NCF in patients undergoing HA-WBRT for brain metastases. To explore this, we performed a secondary analysis of patients enrolled on RTOG 0933, extracting HV from protocol-compliant contours.

Methods

Study design and patients

The methods for RTOG 0933 are described in the published primary analysis. In brief, RTOG 0933 was a single-arm, phase 2 study examining NCF in patients undergoing HA-WBRT compared with historical controls treated with standard WBRT. Eligibility criteria for enrollment were a brain metastasis outside a 5-mm margin around the hippocampus, a pathologically proven diagnosis of nonhematopoetic malignancy other than small cell carcinoma, and recursive partitioning analysis class I or II. Patients younger than 18 years of age and those with leptomeningeval metastases, prior brain-directed radiation therapy, or an inability to undergo MRI were excluded.
Segmentation and radiation therapy planning

All patients underwent 3-dimensional spoiled gradient echo, magnetization prepared rapid gradient echo, or turbo field axial MRI of the brain with axial slice thickness of ≤1.5 mm, which was then fused to computed tomography simulation brain imaging with axial slice thickness ≤2.5 mm. Hippocampal volumes were manually delineated on the fused image set and expanded by 5 mm to generate the hippocampal avoidance regions. The clinical target volume was defined as the whole-brain parenchyma, and the planning target volume was defined as the clinical target volume minus the hippocampal avoidance regions. Intensity modulated radiation therapy was delivered to a dose of 30 Gy in 10 fractions to cover the planning target volume while avoiding the hippocampus. All treating physicians were required to complete dry-run quality assurance testing in image fusion, contouring, and treatment planning for a 5-patient test group before trial participation. Additionally, before individual patient enrollment, central rapid review of HV contours and HA-WBRT planning was conducted in real time before treatment initiation. After completion of 3 protocol-compliant cases, investigators were permitted to enroll subsequent patients without prior central review.

Cognitive assessment

All patients underwent neurocognitive assessment using the Hopkins Verbal Learning Test—Revised (HVLT-R). The HVLT-R has been used as a validated standard for neurocognitive assessment in prior phase 3 cooperative group brain metastasis trials. The HVLT-R consists of a list of 12 nouns with 4 words drawn from 3 semantic categories. To mitigate the effect of repeated administration, a total of 6 different forms were used. Testing consists of memorization of 12 nouns for 3 trials (total recall [HVLT-R TR]), recognition of 12 nouns from a list of related or unrelated items (immediate recall [HVLT-R IR]), and recalling 12 nouns after a 20-minute delay (delayed recall [HVLT-R DR]). Raw scores are derived for these 3 separate domains and then were standardized against normative data to correct for age effects.10 Patients underwent testing at baseline as well as at 2-, 4-, and 6-month follow-up intervals from the start of HA-WBRT and then quarterly until death.

At the completion of RTOG 0933, a total of 113 patients were accrued, of whom 100 were included in the initial analysis. For the purpose of this study, a total of 42 patients were evaluated for the primary endpoint of HVLT-R DR decline at 4 months after exclusions secondary to death, failure to follow up, or inability to obtain imaging. Pretreatment and 4-month NCF scores were obtained. Change scores between baseline and the 4-month time point were calculated by subtracting the follow-up score from the baseline score, such that a positive change score indicated a decline in function. Patients were categorized as deteriorated if they were determined to have a significant decline in NCF at 4 months using a version of the reliable change index11,12 as described in the primary publication of RTOG 0933.

Hippocampal volumes

Centrally submitted radiation therapy plans were obtained for all 42 evaluable patients. Left, right, and total hippocampal volumes were obtained and reported in cubic centimeters. Total brain volume (TBV), inclusive of the hippocampus, was also obtained from radiation therapy plans and reported in cubic centimeters. Using an established method13 to correct for differences in age and sex in hippocampal volumes, a ratio of the hippocampal volume to the total brain volume (corrected hippocampal volume [C-HV] ratio = HV/TBV) was calculated.

Statistical analysis

The C-HV was correlated with baseline and 4-month NCF scores as well as NCF change scores using Pearson correlation coefficients because the data for all patients were approximately normally distributed. The C-HV was also compared between patients with deteriorated and nondeteriorated NCF, as determined by the relative change index, at 4 months, conducted separately for each NCF score (ie, determination of deterioration status for each NCF score and comparison of the C-HV between deteriorated and nondeteriorated NCF) using the Wilcoxon test owing to the small sample size within each deterioration group.

Results

Baseline patient characteristics are presented in Table 1. The median age was 56.5, with 81% of patients having recursive partitioning analysis class II disease. Hippocampal volume data were available for all 42 patients from RTOG 0933. The median baseline total, right, and left HV values were 5.4 cm³ (range, 1.9-7.4 cm³), 2.8 cm³ (range, 0.9-4.0 cm³), and 2.7 cm³ (range, 1.0-3.7 cm³), respectively, and the median baseline total, right and left C-HV values were 0.0041 cm³ (range, 0.0016-0.0052 cm³), 0.0021 cm³ (range, 0.0008-0.0027 cm³), and 0.0019 cm³ (range, 0.0008-0.0019 cm³), respectively (Table 1). The median TBV was 1343 cm³ (range, 1120.5-1738.8 cm³). There was no statistically significant difference in total, right, or left C-HV between deteriorated and nondeteriorated patients (Fig. 1). However, in all instances, patients with deteriorated NCF had a numerically smaller baseline
| Characteristic                                                                 | Patients, No. (%) |
|-------------------------------------------------------------------------------|------------------|
| **Age, y**                                                                    |                  |
| Median                                                                        | 56.5             |
| Range                                                                         | 28-81            |
| Q1-Q3                                                                         | 52-63            |
| <60                                                                           | 27 (64.3)        |
| ≥60                                                                           | 15 (35.7)        |
| **Sex**                                                                       |                  |
| Male                                                                          | 17 (40.5)        |
| Female                                                                        | 25 (59.5)        |
| **Race**                                                                      |                  |
| American Indian or Alaskan Native                                             | 2 (4.8)          |
| Asian                                                                          | 3 (7.1)          |
| Black or African American                                                     | 4 (9.5)          |
| White                                                                          | 30 (71.4)        |
| More than 1 race                                                              | 1 (2.4)          |
| Unknown                                                                       | 2 (4.8)          |
| **Ethnicity**                                                                 |                  |
| Hispanic or Latino                                                            | 2 (4.8)          |
| Not Hispanic or Latino                                                        | 38 (90.5)        |
| Unknown                                                                       | 2 (4.8)          |
| **Karnofsky Performance Status score**                                        |                  |
| 70                                                                            | 6 (14.3)         |
| 80                                                                            | 4 (9.5)          |
| 90                                                                            | 19 (45.2)        |
| 100                                                                           | 13 (31.0)        |
| **RPA class**                                                                 |                  |
| I                                                                             | 8 (19.0)         |
| II                                                                            | 34 (81.0)        |
| **Neurologic function status**                                                |                  |
| No symptoms                                                                   | 29 (69.0)        |
| Symptoms                                                                      | 13 (31.0)        |
| **Total HV, cm³**                                                            |                  |
| Mean                                                                          | 5.4              |
| SD                                                                            | 1.2              |
| Median                                                                        | 5.5              |
| Range                                                                         | 1.9-7.4          |
| Q1-Q3                                                                         | 4.8-6.1          |

(continued)

| Characteristic                                                                 | Patients, No. (%) |
|-------------------------------------------------------------------------------|------------------|
| **Right HV, cm³**                                                            |                  |
| Mean                                                                          | 2.7              |
| SD                                                                            | 0.6              |
| Median                                                                        | 2.8              |
| Range                                                                         | 0.9-4.0          |
| Q1-Q3                                                                         | 2.4-3.1          |
| **Left HV, cm³**                                                             |                  |
| Mean                                                                          | 2.6              |
| SD                                                                            | 0.6              |
| Median                                                                        | 2.7              |
| Range                                                                         | 1.0-3.7          |
| Q1-Q3                                                                         | 2.3-3.0          |
| **Total intracranial volume, cm³**                                            |                  |
| Mean                                                                          | 1373.4           |
| SD                                                                            | 157.5            |
| Median                                                                        | 1343.0           |
| Range                                                                         | 1120.5-1738.8    |
| Q1-Q3                                                                         | 1273.4-1476.8    |
| **Total C-HV, cm³**                                                          |                  |
| Mean                                                                          | 0.0039           |
| SD                                                                            | 0.0008           |
| Median                                                                        | 0.0041           |
| Range                                                                         | 0.0016-0.0052    |
| Q1-Q3                                                                         | 0.0036-0.0045    |
| **Right C-HV, cm³**                                                          |                  |
| Mean                                                                          | 0.0020           |
| SD                                                                            | 0.0004           |
| Median                                                                        | 0.0021           |
| Range                                                                         | 0.0008-0.0027    |
| Q1-Q3                                                                         | 0.0018-0.0023    |
| **Left C-HV, cm³**                                                           |                  |
| Mean                                                                          | 0.0019           |
| SD                                                                            | 0.0004           |
| Median                                                                        | 0.0019           |
| Range                                                                         | 0.0008-0.0025    |
| Q1-Q3                                                                         | 0.0017-0.0023    |

Abbreviations: C-HV = corrected hippocampal volume; Q1 = first quartile; Q3 = third quartile; RPA = recursive partitioning analysis; SD = standard deviation.

* Data are presented as the number and percentage of patients unless otherwise indicated.
total HV. The total, right, and left C-HVs were significantly correlated with HVLT-R recall and delayed recall but not with recognition at baseline (Table 2). The total, right, and left C-HVs correlated with HVLT-R recall and delayed recall but not with recognition at 4 months (Table 3). There was no significant correlation between C-HVs and change scores from baseline to 4 months for any measure of HVLT.

**Discussion**

Neurocognitive toxic effects associated with WBRT are a well-recognized issue. With improvements in systemic therapies leading to increased overall survival, prophylactic mitigation of the deleterious effects of WBRT remain of great interest. Memantine and HA-WBRT have both demonstrated protective effects for NCF relative to standard WBRT. Although these interventions are feasible, important considerations must be given to survival, cost, time, and the pathogenesis and incidence of neurocognitive toxic effects. An improved ability to predict neurocognitive toxic effects would allow clinicians to more appropriately select radiotherapeutic options. Patient-specific variables have predictive value for NCF in patients with neurodegenerative disease. One such marker is HV. In this secondary analysis of RTOG 0933, we found that all measures of HV correlated with HVLT-R recall and delayed recall at baseline and 4 months. This result was consistent with those of prior studies in neurodegenerative disease. Multiple studies have noted a strong correlation between hippocampal volume and Alzheimer disease. More recently, Petersen et al and others have reported a correlation with HV not just for Alzheimer disease but across a spectrum of cognitive dysfunction, from normal aging to mild cognitive impairment.

| C-HV | HVLT-R score | Recollection | Delayed recall | Recognition |
|------|--------------|--------------|----------------|-------------|
| Total | $\rho$  | 0.38 | 0.37 | 0.045 |
| | $P$ value* | 0.013 | 0.0090 | 0.78 |
| Right | $\rho$ | 0.34 | 0.35 | $-0.0046$ |
| | $P$ value* | 0.029 | 0.014 | 0.98 |
| Left | $P$ | 0.39 | 0.35 | 0.092 |
| | $P$ value* | 0.012 | 0.024 | 0.56 |

*Abbreviations: C-HV = corrected hippocampal volume; HVLT-R = Hopkins Verbal Learning Test—Revised. * $P$ value from Pearson correlation coefficient.
Hippocampal volume did not significantly correlate with change scores in any measure of HVLT. This is likely secondary to the fact that all patients received HA-WBRT, and therefore, the lack of correlation may be seen as additional evidence supporting the role of HA-WBRT in sparing NCF decline. There were also a limited number of patients; more patients may be needed to detect any correlation between baseline HV and decline in NCF.

The HVLT-R scores at baseline and 4 months and the change score were not correlated with HV. The lack of correlation between recognition testing and HV is not surprising. The prefrontal, parietal, and medial temporal cortices have been shown to be responsible for recognition memory. Functional magnetic resonance and lesion studies have demonstrated that changes in these neuroanatomic regions result in significant change in recognition testing. Although the hippocampus has been demonstrated to be responsible for portions of recognition, it is evident that hippocampal volume alone is unlikely to result in significant change in recognition testing.

Despite these hypothesis-generating results, this study has a number of limitations. First, in the primary analysis, 113 patients were enrolled, but only 42 were analyzable secondary to exclusions for ineligibility, death, and non-compliance with follow-up at 4 months. As a result, the total number of patients was limited and may not be representative of a larger cohort. Second, the ability to control for additional confounding variables is narrow, partly owing to the limited number of patients. Tumor- and treatment-related factors such as white matter change (unpublished data), as well as other neuropsychiatric diseases, are known to affect cognition independently of HV. Additionally, HV and its correlation with NCF in this study were limited to a single time interval. Analysis including pretreatment brain MRI, such as that for newly diagnosed stage III non small cell lung cancer, or follow-up brain MRI would be more robust. Lastly, the ability to assess the effect of hippocampal volume on neurocognitive function was incomplete. Although the HVLT is a validated assessment and has been used in multiple studies in the treatment of brain metastasis, our ability to discern effects on other measures of neurocognition was limited. However, despite these limitations, the available data represent a product of a robust quality assurance protocol. Investigators were required to complete pre-enrollment hippocampal contouring training, and each case was centrally reviewed in a prospective fashion. Additionally, neurocognitive testing was performed by centrally certified research assistants. NRG CC003, a phase II/III trial of prophylactic cranial irradiation with or without HA for small cell lung cancer, has addressed a number of these limitations with increased patient enrollment and a more robust battery of neurocognitive assessments such as controlled oral word association and the trail making test.

### Conclusion

Hippocampal volume is predictive of neurocognitive function in patients with brain metastasis undergoing hippocampal-avoidant whole brain radiation therapy at baseline and 4 months. Given this, hippocampal volume may potentially serve as a metric to better characterize NCF to tailor therapy; however, continued investigation is needed. NRG CC001 and CC003 are currently under way and have the potential to answer these clinically relevant questions.

### References

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. *CA Cancer J Clin*. 2012;62:10–29.
2. Kann BH, Park HS, Johnson SB, Chiang VL, Yu JB. Radiosurgery for brain metastases: Changing practice patterns and disparities in the United States. *J Natl Compr Canc Netw*. 2017;15:1494–1502.
3. Brown PD, Jaeckle K, Ballman KV, et al. Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases: A randomized clinical trial. *JAMA*. 2016;316:401–409.
4. Brown PD, Pugh S, Laack NN, et al. Radiation therapy oncology group (RTOG). Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: A randomized,
double-blind, placebo-controlled trial. *Neuro Oncol.* 2013;15:1429–1437.

5. Eriksson PS, Perfilieva E, Björk-Eriksson T, et al. Neurogenesis in the adult human hippocampus. *Nat Med.* 1998;4:1313–1317.

6. Gondi V, Pugh SL, Tome WA, et al. Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): A phase II multi-institutional trial. *J Clin Oncol.* 2014;32:3810–3816.

7. Brown PD, Gondi V, Pugh S, et al. Hippocampal avoidance during whole-brain radiotherapy plus memantine for patients with brain metastases: Phase III trial NRG oncology CC001. *J Clin Oncol.* 2020;38:1019–1029.

8. Kantarci K, Weigand SD, Przybelski SA, et al. MRI and MRS predictors of mild cognitive impairment in a population-based sample. *Neurology.* 2013;81:126–133.

9. Fleischman DA, Yu L, Arfanakis K, et al. Faster cognitive decline in the years prior to MR imaging is associated with smaller hippocampal volumes in cognitively healthy older persons. *Front Aging Neurosci.* 2013;5:21.

10. Benedict RHB, Schretlen D, Groninger L, Brandt J. Hopkins Verbal Learning Test — Revised: Normative data and analysis of inter-form and test-retest reliability. *Clin Neuropsychol.* 1998;12:43–55.

11. Chelune GJ, Naugle RL, Lüders H, Sedlak J, Awad IA. Individual change after epilepsy surgery: Lüders H, Sedlak J, Awad IA. Individual change after epilepsy surgery: Practice effects and base-rate information. *Neuropsychology.* 1993;7:41–52.

12. Jacobson NS, Truax P. Clinical significance: A statistical approach to defining meaningful change in psychotherapy research. *J Consult Clin Psychol.* 1991;59:12–19.

13. Voevodskaya O, Simmons A, Nordenskjöld R, et al. Alzheimer’s Disease Neuroimaging Initiative, 2014. The effects of intracranial volume adjustment approaches on multiple regional MRI volumes in healthy aging and Alzheimer’s disease. *Front Aging Neurosci.* 1991;6:264.

14. Wolfson AH, Bae K, Komaki R, et al. Primary analysis of a phase II randomized trial Radiation Therapy Oncology Group (RTOG) 0212: Impact of different total doses and schedules of prophylactic cranial irradiation on chronic neurotoxicity and quality of life for patients with limited-disease small-cell lung cancer. *Int J Radiat Oncol Biol Phys.* 2011;81:77–84.

15. Convit A, De Leon MJ, Tarshish G, et al. Specific hippocampal volume reductions in individuals at risk for Alzheimer’s disease. *Neurol Biol Aging.* 1997;18:131–138.

16. Jack CR, Petersen RC, Xu Y, et al. Rate of medial temporal lobe atrophy in typical aging and Alzheimer’s disease. *Neurology.* 1998;51:993–999.

17. Jack CR, Petersen RC, Xu YC, et al. Medial temporal atrophy on MRI in normal aging and very mild Alzheimer’s disease. *Neurology.* 1997;49:786–794.

18. Petersen RC, Jack CR, Xu YC, et al. Memory and MRI-based hippocampal volumes in aging and AD. *Neurology.* 2000;54:581–587.

19. Yonelinas AP, Otten LJ, Shaw KN, Rugg MD. Separating the brain regions involved in recollection and familiarity in recognition memory. *J Neurosci.* 2005;25:3002–3008.

20. MacPherson SE, Turner MS, Bozzali M, Cipolotti L, Shallice T. The doors and people test: The effect of frontal lobe lesions on recall and recognition memory performance. *Neuropsychology.* 2016;30:332–337.

21. MacQueen GM, Campbell S, McEwen BS, et al. Course of illness, hippocampal function, and hippocampal volume in major depression. *Proc Natl Acad Sci USA.* 2003;100:1387.